Pharmacological Activation of Pyruvate Kinase M2 Inhibits CD4+-T Cell 
Pathogenicity and Suppresses Autoimmunity

Angiari, Stefano; Runtsch, Marah C.; Sutton, Caroline E.; Palsson-McDermott, Eva M.; Kelly, Beth; Rana, Nisha; Kane, Harry; Papadopoulou, Gina; Pearce, Erika L.; Mills, Kingston H.G.; O'Neill, Luke A.J.

doi:org/10.1016/j.cmet.2019.10.015

アイテム詳細

登録内容を編集ファイル形式で保存

一時保存へ追加

タグ情報を表示リリース履歴を表示詳細要約

公開

学術論文

Pharmacological Activation of Pyruvate Kinase M2 Inhibits CD4⁺-T Cell Pathogenicity and Suppresses Autoimmunity

MPS-Authors

/persons/resource/persons201431

Pearce, Erika L.
Department Immunometabolism, Max Planck Institute of Immunobiology and Epigenetics, Max Planck Society;

External Resource

https://www.sciencedirect.com/science/article/pii/S1550413119306060?via%3Dihub
(出版社版)

Fulltext (restricted access)

There are currently no full texts shared for your IP range.

フルテキスト (公開)

公開されているフルテキストはありません

付随資料 (公開)

There is no public supplementary material available

引用

Angiari, S., Runtsch, M. C., Sutton, C. E., Palsson-McDermott, E. M., Kelly, B., Rana, N., Kane, H., Papadopoulou, G., Pearce, E. L., Mills, K. H., & O'Neill, L. A. (2020). Pharmacological Activation of Pyruvate Kinase M2 Inhibits CD4⁺-T Cell Pathogenicity and Suppresses Autoimmunity. Cell Metabolism, 31, 391-405. doi:org/10.1016/j.cmet.2019.10.015.

引用: https://hdl.handle.net/21.11116/0000-0006-3C98-C

要旨

Pyruvate kinase (PK) catalyzes the conversion of phosphoenolpyruvate to pyruvate during glycolysis. The PK isoform PKM2 has additional roles in regulation of gene transcription and protein phosphorylation. PKM2 has been shown to control macrophage metabolic remodeling in inflammation, but its role in T cell biology is poorly understood. Here, we report PKM2 upregulation, phosphorylation, and nuclear accumulation in murine and human CD4+ T cells following activation in vitro. Treatment of T cells with TEPP-46, an allosteric activator that induces PKM2 tetramerization and blocks its nuclear translocation, strongly reduces their activation, proliferation, and cytokine production by inhibiting essential signaling pathways and thus preventing the engagement of glycolysis. TEPP-46 limits the development of both T helper 17 (Th17) and Th1 cells in vitro and ameliorates experimental autoimmune encephalomyelitis (EAE) in vivo. Overall, our results suggest that pharmacological targeting of PKM2 may represent a valuable therapeutic approach in T cell-mediated inflammation and autoimmunity.